Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

This phase II trial investigates two strategies and how well they work for the reduction of graft versus host disease in patients with acute leukemia or MDS in remission. Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient, they may help the patient's bone marrow make stem cells

Trial Details

NCT ID

NCT03970096

Phase

PHASE2

Sponsor

Fred Hutchinson Cancer Center

Status

RECRUITING

Cancer Type

Leukemia

Interventions

Total-Body Irradiation
Thiotepa
Fludarabine
Tacrolimus
Allogeneic CD34+-enriched and CD45RA-depleted PBSCs
Methotrexate

Locations (sample)

Tampa, Florida, United States|27.94752,-82.45843
Pittsburgh, Pennsylvania, United States|40.44062,-79.99589
Seattle, Washington, United States|47.60621,-122.33207

Key Eligibility Criteria

Patients who are considered appropriate candidates for myeloablative, TBI-containing allogeneic hematopoietic stem cell transplantation and have on…
Acute lymphocytic leukemia (ALL) in first or subsequent morphological remission (\< 5% marrow blasts by morphology).
Acute myeloid leukemia (AML) in first or subsequent morphological remission (\< 5% marrow blasts by morphology).
Other acute leukemia or related neoplasm (including but not limited to 'mixed phenotype' 'biphenotypic', 'acute undifferentiated' or 'ambiguous lin…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →